"The
Report OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) -
Opportunity Analysis and Forecasts to 2024 provides information on
pricing, market analysis, shares, forecast, and company profiles for
key industry participants. - MarketResearchReports.biz"
Human
respiratory syncytial virus (RSV)
is an enveloped, single-stranded, negative-sense ribonucleic acid
(RNA) pneumovirus belonging to the family of Paramyxoviridae. The
virus was discovered in 1956, first as an isolate from a laboratory
chimpanzee displaying symptoms of the common cold, and later from
infants suffering from respiratory disease. RSV can cause upper
respiratory tract infections (the common cold) and is the most
important cause of lower respiratory tract infections, such as
bronchiolitis and pneumonia, in infants. RSV is also an important
cause of hospitalizations and deaths in elderly adults.
Today,
Medimmunes Synagis (palivizumab) is the only licensed intervention
for the prevention of RSV in infants at a high risk of severe
infection. This humanized, mouse monoclonal antibody (mAb) was first
approval in 1998, and while it is an efficacious prophylactic
intervention, its short 20-day half-life necessitates monthly dosing
during the RSV season. Moreover, the high cost of Synagis limits its
use to certain subgroups of infants who are at high risk of severe
RSV infection, and it is not indicated for use in elderly adults,
leaving a key population of high-risk individuals unprotected.
Furthermore, due to the absence of effective RSV-specific antivirals,
the treatment of RSV infections is largely restricted to a number of
supportive treatment options. GlobalData projects the global RSV
marketplace - which, for the purposes of this report, comprises the
seven major pharmaceutical markets (7MM; US, France, Germany, Italy,
Spain, UK, Japan) - to experience unprecedented growth from
2014-2024, driven by the arrival of novel approaches to prevention
and management of RSV.
Download Sample copy of this
Report at
Highlights
Key Questions Answered
-
Based on interviews with key opinion leaders (KOLs), GlobalData has
identified the major unmet needs in the RSV marketplace. Will the
leading pipeline agents fulfil these unmet needs during the forecast
period (2014-2024)?
-
What research and development (R&D) strategies will companies
leverage to
compete
in the future RSV marketplace?
-
Which patient population(s) are most likely to be targeted by novel
RSV prophylactic and therapeutic agents?
-
What clinical and commercial factors are likely to influence RSV
product uptake in the 7MM?
Key Findings
-
The global RSV marketplace - which, for the purposes of this report,
encompasses the sales of products for the prevention or treatment of
RSV in the 7MM - was worth approximately $640m in 2014. GlobalData
projects the market to surpass $2.3bn in sales by 2024, at a compound
annual growth rate (CAGR) of 29.9% from 2014-2024. The sales are
projected to originate predominantly from the US (a 62% market
share), followed distantly by the 5EU (a 29% market share).
-
The anticipated arrival of novel prophylactic mAbs that boast
improved dosing criteria compared with Synagis, led by MedImmunes
MEDI8897, will be a principal driver of RSV market growth across the
7MM. The licensure of the first adult vaccine to offer protection
against RSV, Novavaxs RSV-F Vaccine, will also stimulate rapid growth
in a previously untapped segment of the marketplace.
-
A persistent lack of patient and physician awareness of RSV in adult
patients - specifically the infections substantial impact on
morbidity and mortality in the elderly - will serve as a key
impediment to market growth from 2014-2024.
Follow us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
Scope
-
Overview of RSV infections, including epidemiology, etiology,
pathophysiology, symptoms, diagnosis, and current management
strategies.
-
Topline RSV market revenue from 2014-2024. Annual cost of therapy
(ACOT) and major pipeline product sales in this forecast period are
included.
-
Key topics covered include current treatment options, unmet needs and
opportunities, and the drivers and barriers affecting RSV product
sales in the 7MM.
-
Pipeline analysis: comprehensive data split across different phases,
emerging novel trends under development, synopses of innovative
early-stage projects, and detailed analysis of late-stage pipeline
products.
-
Analysis of the current and future market competition in the global
RSV market. Insightful review of the key industry drivers, restraints
and challenges. Each trend is independently researched to provide
qualitative analysis of its implications.
Reasons to buy
The
report will enable you to -
-
Develop and design your in-licensing and out-licensing strategies
through a review of pipeline products and technologies, and by
identifying the companies with the most robust pipeline.
-
Develop business strategies by understanding the trends shaping and
driving the global RSV market.
-
Drive revenues by understanding the key trends, innovative products
and technologies, market segments, and companies likely to impact the
RSV market in the future.
-
Formulate effective sales and marketing strategies by understanding
the competitive landscape and by analyzing the performance of various
competitors.
-
Identify emerging players with potentially strong product portfolios
and create effective counter-strategies to gain a competitive
advantage.
-
Organize your sales and marketing efforts by identifying the market
categories and segments that present maximum opportunities for
consolidations, investments, and strategic partnerships.
Read our latest Press
Release at http://www.marketresearchreports.biz/pressreleases
Table of Contents
1 Table of Contents 10
1.1 List of Tables 15
1.2 List of Figures 18
2 Introduction 19
2.1 Catalyst 19
2.2 Related Reports 20
2.3 Upcoming Related Reports 21
3 Disease Overview 22
3.1 Etiology and
Pathophysiology 22
3.1.1 Etiology 22
3.1.2 Pathophysiology 26
3.2 Symptoms and Prognosis 28
3.2.1 Symptoms 28
3.2.2 Prognosis 30
3.3 Quality of Life 31
3.4 Disease Management 31
3.4.1 Diagnosis of RSV
Infection 32
3.4.2 Prevention of RSV
Infection 34
3.4.3 Treatment of RSV
Infection 37
4 Epidemiology 40
4.1 Disease Background 40
4.2 Risk Factors and
Comorbidities 41
4.3 Global Trends 43
4.3.1 Preterm Infants and
Children Born Preterm and Survived to Two Years of Age 44
4.3.2 Infants with Neonatal CLD
44
4.3.3 Children with
Hemodynamically Significant Congenital Heart Disease 45
4.3.4 Children with Congenital
Respiratory or Neuromuscular Diseases That Compromise Respiratory
Function 45
4.3.5 Third-Trimester Pregnant
Women 46
4.3.6 Hospitalizations for RSV
Infection 47
4.4 Forecast Methodology 48
4.4.1 Sources Used 54
4.4.2 Sources Not Used 62
4.4.3 Forecast Assumptions and
Methods 63
4.5 Epidemiological Forecast
for RSV Infection (2014-2024) 72
4.5.1 Risk Groups for Severe
RSV Infection in Children Less than Two Years 72
4.5.2 Preterm Births 78
4.5.3 Neonatal CLD 79
4.5.4 Third-Trimester Pregnant
Women 80
4.5.5 RSV Hospitalizations in
Children 81
4.6 Discussion 83
4.6.1 Epidemiological Forecast
Insight 83
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment